Karuna Therapeutics (Karuna Therapeutics) Cash-to-Debt : 75.67 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Karuna Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Karuna Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 75.67.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Karuna Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Karuna Therapeutics's Cash-to-Debt or its related term are showing as below:

KRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 75.67 Max: 1872.1
Current: 75.67

During the past 7 years, Karuna Therapeutics's highest Cash to Debt Ratio was 1872.10. The lowest was 0.17. And the median was 75.67.

KRTX's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.49 vs KRTX: 75.67

Karuna Therapeutics Cash-to-Debt Historical Data

The historical data trend for Karuna Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Karuna Therapeutics Cash-to-Debt Chart

Karuna Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1,872.10

120.05

65.84

210.97

75.67

Karuna Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															210.97	309.82	90.86	85.95	75.67

Competitive Comparison of Karuna Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Karuna Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karuna Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karuna Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Karuna Therapeutics's Cash-to-Debt falls into.

Karuna Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Karuna Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1262.813	/	(2.843	+	13.845)
	=	75.67

Karuna Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1262.813	/	(2.843	+	13.845)
	=	75.67

Karuna Therapeutics (NAS:KRTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Karuna Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Karuna Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Karuna Therapeutics (Karuna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karuna Therapeutics Inc (NAS:KRTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

KRTX:Mexico

Address

99 High Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.karunatx.com

Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.

Executives

Stephen K. Brannan	officer: Chief Medical Officer	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jason Parker Brown	officer: Chief Financial Officer	KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Jeffrey M Jonas	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Troy A. Ignelzi	officer: Chief Financial Officer	C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Andrew Craig Miller	officer: Chief Operating Officer	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Laurie J Olson	director	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Kane William P Jr	officer: Chief Commercial Officer	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
William Meury	director, officer: President and CEO	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Charmaine Lykins	officer: Chief Commercial Officer	C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Steven M Paul	director, officer: President & CEO	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Puretech Health Llc	10 percent owner	501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045